We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Brain Stimulation System Treats Tremor Patients

By HospiMedica International staff writers
Posted on 29 Oct 2014
Innovative deep-brain stimulation (DBS) system provides precise neural targeting to customize therapy for patients with tremor.

The Vercise DBS system is intended for patients with Parkinson’s disease (PD), primary and secondary dystonia, and essential tremor (ET). More...
The system impulse generator (IPG) possesses a gentle, contoured oval shape with a small footprint of just 20 cm2. The IPG is accompanied by a multilumen lead that includes 8 contacts and a broad span. Targeting is achieved using a multiple independent current control (MICC) platform, which allows selective control of the electric current delivered through each individual electrode.

Unique rechargeable battery technology proffers the system with a 25 year life span, helping to reduce surgical interventions; and zero Volt battery technology ensures that even if the battery is completely discharged, there will be no failure or damage. The charging system, as is the remote control, are completely cordless, allowing patients to remain active. The Vercise DBS system is a product of Boston Scientific (Natick, MA, USA), and has received the European Community CE marking of approval.

“With the launch of the Vercise DBS System for the treatment of patients with Parkinson's disease in 2012, for dystonia in 2013, and now for tremor, Boston Scientific continues to demonstrate its commitment to provide more access to DBS therapy to more patients,” said Maulik Nanavaty, president of neuromodulation at Boston Scientific. “We believe this advanced technology can play a critical role in improving the lives of patients who suffer from these devastating conditions.”

“Essential tremor can be very debilitating for patients in their day-to-day activities such as writing and eating,” said Prof. Veerle Visser Vandewalle, MD, of University Hospital Cologne (Germany), who implanted the first European system. “The Vercise DBS System provides advanced tremor care through precise neural targeting that is designed to manage ET symptoms effectively and improve patient quality of life.”

ET is a neurological disorder that causes a rhythmic shaking, and can affect almost any part of the body, but occurs most often in the hands, especially when intent is present, such as drinking from a glass, holding a fork, writing, or shaving. Although not a dangerous condition, ET worsens over time. It can occur at any age, but is most common in people age 40 and older.

Related Links:

Boston Scientific



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.